Literature DB >> 31776207

5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Epiphani C Simmons1, Natalie E Scholpa1, Kristan H Cleveland1, Rick G Schnellmann2.   

Abstract

Spinal cord injury (SCI) is characterized by vascular disruption leading to ischemia, decreased oxygen delivery, and loss of mitochondrial homeostasis. This mitochondrial dysfunction results in loss of cellular functions, calcium overload, and oxidative stress. Pharmacological induction of mitochondrial biogenesis (MB) may be an effective approach to treat SCI. LY344864, a 5-hydroxytryptamine 1F (5-HT1F) receptor agonist, is a potent inducer of MB in multiple organ systems. To assess the efficacy of LY344864-induced MB on recovery post-SCI, female mice were subjected to moderate force-controlled impactor-induced contusion SCI followed by daily LY344864 administration for 21 days. Decreased mitochondrial DNA and protein content was present in the injury site 3 days post-SCI. LY344864 treatment beginning 1 h after injury attenuated these decreases, indicating MB. Additionally, injured mice treated with LY344864 displayed decreased Evan's Blue dye accumulation in the spinal cord compared with vehicle-treated mice 7 days after injury, suggesting restoration of vascular integrity. LY344864 also increased locomotor capability, with treated mice reaching a Basso-Mouse Scale score of 3.4 by 21 days, whereas vehicle-treated mice exhibited a score of 1.9. Importantly, knockout of the 5-HT1F receptor blocked LY344864-induced recovery. Remarkably, a similar degree of locomotor restoration was observed when treatment initiation was delayed until 8 h after injury. Furthermore, cross-sectional analysis of the spinal cord 21 days after injury revealed decreased lesion volume with delayed LY344864 treatment initiation, emphasizing the potential clinical applicability of this therapeutic approach. These data provide evidence that induction of MB via 5-HT1F receptor agonism may be a promising strategy for the treatment of SCI. SIGNIFICANCE STATEMENT: Treatment with LY344864 induces mitochondrial biogenesis in both the naive and injured mouse spinal cord. In addition, treatment with LY344864 beginning after impactor-induced contusion spinal cord injury improves mitochondrial homeostasis, blood-spinal cord barrier integrity, and locomotor function within 7 days. Importantly, similar locomotor results are observed whether treatment is initiated at 1 h after injury or 8 h after injury. These data indicate the potential for pharmacological induction of mitochondrial biogenesis through a 5-hydroxytryptamine 1F agonist as a novel therapeutic approach for spinal cord injury. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31776207      PMCID: PMC6978694          DOI: 10.1124/jpet.119.262410

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

Review 1.  Epidemiology of traumatic spinal cord injury: trends and future implications.

Authors:  M J Devivo
Journal:  Spinal Cord       Date:  2012-01-24       Impact factor: 2.772

Review 2.  Antioxidant therapies for acute spinal cord injury.

Authors:  Edward D Hall
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 3.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

4.  Matrix Metalloproteinase-8 Inhibition Prevents Disruption of Blood-Spinal Cord Barrier and Attenuates Inflammation in Rat Model of Spinal Cord Injury.

Authors:  Hemant Kumar; Min-Jae Jo; Hyemin Choi; Manjunatha S Muttigi; Seil Shon; Byung-Joo Kim; Soo-Hong Lee; In-Bo Han
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

5.  Agonism of the 5-hydroxytryptamine 1F receptor promotes mitochondrial biogenesis and recovery from acute kidney injury.

Authors:  Sara M Garrett; Ryan M Whitaker; Craig C Beeson; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2014-05-21       Impact factor: 4.030

Review 6.  Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward?

Authors:  Alexander G Rabchevsky; Samir P Patel; Joe E Springer
Journal:  Pharmacol Ther       Date:  2011-05-14       Impact factor: 12.310

7.  A high-throughput respirometric assay for mitochondrial biogenesis and toxicity.

Authors:  Craig C Beeson; Gyda C Beeson; Rick G Schnellmann
Journal:  Anal Biochem       Date:  2010-05-11       Impact factor: 3.365

8.  Effect of VEGF treatment on the blood-spinal cord barrier permeability in experimental spinal cord injury: dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Chirag B Patel; David M Cohen; Pallavi Ahobila-Vajjula; Laura M Sundberg; Tessy Chacko; Ponnada A Narayana
Journal:  J Neurotrauma       Date:  2009-07       Impact factor: 5.269

9.  Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury.

Authors:  Yang D Teng; Howard Choi; Renna C Onario; Shan Zhu; Federico C Desilets; Shoumin Lan; Eric J Woodard; Evan Y Snyder; Marc E Eichler; Robert M Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

10.  The cross-talk between autophagy and endoplasmic reticulum stress in blood-spinal cord barrier disruption after spinal cord injury.

Authors:  Yulong Zhou; Yanqing Wu; Yanlong Liu; Zili He; Shuang Zou; Qingqing Wang; Jiawei Li; Zengming Zheng; Jian Chen; Fenzan Wu; Fanhua Gong; Hongyu Zhang; Huazi Xu; Jian Xiao
Journal:  Oncotarget       Date:  2017-01-03
View more
  5 in total

Review 1.  [Advances of the role of mitochondrial dysfunction in the spinal cord injury and its relevant treatments].

Authors:  Xin Miao; Junqing Lin; Xianyou Zheng
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-07-15

2.  FDA-approved 5-HT1F receptor agonist lasmiditan induces mitochondrial biogenesis and enhances locomotor and blood-spinal cord barrier recovery after spinal cord injury.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2021-04-10       Impact factor: 5.620

3.  Sodium alginate and naloxone loaded macrophage-derived nanovesicles for the treatment of spinal cord injury.

Authors:  Xiaoyao Liu; Xue Jiang; Qi Yu; Wenwen Shen; He Tian; Xifan Mei; Chao Wu
Journal:  Asian J Pharm Sci       Date:  2021-11-14       Impact factor: 6.598

4.  5-HT1F Receptor Agonist Ameliorates Mechanical Allodynia in Neuropathic Pain via Induction of Mitochondrial Biogenesis and Suppression of Neuroinflammation.

Authors:  Long-Qing Zhang; Ya-Qun Zhou; Jia-Yan Li; Jia Sun; Shuang Zhang; Jia-Yi Wu; Shao-Jie Gao; Xue-Bi Tian; Wei Mei
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.810

5.  Photobiomodulation promotes repair following spinal cord injury by restoring neuronal mitochondrial bioenergetics via AMPK/PGC-1α/TFAM pathway.

Authors:  Zhijie Zhu; Xuankang Wang; Zhiwen Song; Xiaoshuang Zuo; Yangguang Ma; Zhihao Zhang; Cheng Ju; Zhuowen Liang; Kun Li; Xueyu Hu; Zhe Wang
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.